George Lundberg, MD Editor in Chief at Cancer Commons
-
September 6, 2022
Molecular Alterations Associated With Improved Outcome in Patients With Glioblastoma Treated With Tumor-Treating Fields Bookmark
George Lundberg, MDDo molecular biomarkers have any role in treating glioblastoma (GBM)? As outlined in this scientific research report from the academic journal Neuro-Oncology Research Advances, a recent study found that 3 biomarkers were correlated with very great outcome differences for people treated with tumor-treating (electrical) fields.
.
.
-
September 6, 2022
Brain Tumor Guide Bookmark
George Lundberg, MDThe Musella Foundation has announced online availability of the 12th edition of the Brain Tumor Guide for the Newly Diagnosed.
.
-
September 6, 2022
‘Clinically Meaningful’ Improvement in SCLC Patients With Pembrolizumab/Chemo Combo Bookmark
George Lundberg, MDAs reported by MedPage Today, long-term results from a clinical trial suggest that a combination of the drug pembrolizumab plus chemotherapy is better than chemo alone for small cell lung cancer (SCLC). But unfortunately, most patients who received the combo did not benefit significantly, and biomarkers are very much needed to identify patients whose cancers will respond well.
.
-
August 5, 2022
FDA Approves Two Nivolumab-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma Bookmark
George Lundberg, MDThe ASCO Post reports on the U.S. Food And Drug Administration (FDA)’s recent approval of two new treatments for advanced, unresectable squamous cell carcinoma of the esophagus.
.
-
August 5, 2022
Summary of Kidney Cancer Highlights from ASCO GU 2022 Bookmark
George Lundberg, MDThis article from the International Kidney Cancer Coalition (IKCC) outlines updates on treatment options for renal cell carcinoma as presented at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium.
.
-
August 5, 2022
Good for Bladder Cancer, Better for Kidney Cancer Bookmark
George Lundberg, MDThis article from the National Cancer Institute’s Center for Cancer Research outlines new clinical trial results showing that combining the drugs cabozantinib and nivolumab doubled progression-free survival for people with advanced renal cell carcinoma compared to giving cabozantinib alone.
.
-
August 5, 2022
Recent Advances in Systemic Therapy for Hepatocellular Carcinoma Bookmark
George Lundberg, MDThis review article in the academic research journal Biomarker Research discusses how combining immunotherapy and targeted therapies provides new hope for people with hepatocellular carcinoma.
.
-
August 5, 2022
Treatment Approaches for Advanced Hepatocellular Carcinoma: Insight From the 2022 Gastrointestinal Cancers Symposium Bookmark
George Lundberg, MDIn this article for Cancer Therapy Advisor, Dr. Shaalan Beg shares updates from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium on treatments for advanced hepatocellular carcinoma.
.
-
August 5, 2022
Adagrasib in Previously Treated Patients With KRAS G12C–Mutated Advanced NSCLC Bookmark
George Lundberg, MDAs reported by The ASCO Post, the drug adagrasib has shown some promising results in a clinical trial for people with advanced non-small cell lung cancer (NSCLC) with a KRAS-g12c mutation whose cancer progressed after prior treatment. The U.S. Food and Drug Administration (FDA) allows adagrasib to be given to people whose cancer has a KRAS-g12c mutation through expanded access.
.
-
July 30, 2022
Deciphering the Elusive Origin and Pathways of Brain Metastases Bookmark
George Lundberg, MDThe most common brain tumors are other types of cancer that have spread (or “metastasized”) to the brain from a primary site elsewhere in the body. And, the genomic makeup of the brain metastases may not be the same as the primary cancer. An article from The ASCO Post discusses what this means for treatment.
.